Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Circulating tumor cells (CTCs) are valuable circulating biomarkers of cancer, which carry primary tumor information and may provide real-time assessment of tumor status as well as treatment response in cancer patients. Herein, we developed a novel assay for accurate diagnosis and dynamic monitoring of epithelial ovarian cancer (EOC) using CTC RNA analysis. Multiantibody-modified magnetic nanoparticles were prepared for purification of EOC CTCs from whole blood samples of clinical patients. Subsequently, nine EOC-specific mRNAs of purified CTCs were quantified using droplet digital PCR. The EOC CTC Score was generated using a multivariate logistic regression model for each sample based on the transcripts of the nine genes. This assay exhibited a distinguishing diagnostic performance for the detection of EOC ( = 17) from benign ovarian tumors ( = 30), with an area under the receiver operating characteristic curve (AUC) of 0.96 (95% CI = 0.91-1.00). Moreover, dynamic changes of the EOC CTC Score were observed in patients undergoing treatment, demonstrating the potential of the assay for monitoring EOC. In conclusion, we present an accurate assay for the diagnosis and monitoring of EOC via CTC RNA analysis, and the results suggest that it may provide a promising solution for the detection and treatment response assessment of EOC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acssensors.3c01063 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A pilot study evaluating the feasibility of enriching and detecting circulating tumour cells from peripheral and ovarian veins in rare epithelial ovarian carcinomas.
Eur J Surg Oncol
April 2025
Department of Histopathology, School of Medicine, Trinity College Dublin, Dublin, Ireland; Department of Obstetrics and Gynaecology, School of Medicine, Trinity College Dublin, Dublin, Ireland; Trinity St. James's Cancer Institute, Trinity College Dublin, Dublin, Ireland. Electronic address: shotool
Introduction: Studies on circulating tumour cells (CTCs) in rare epithelial ovarian carcinomas (EOC) are limited, despite their potential as a minimally invasive biomarker for monitoring cancer progression and predicting outcomes. This pilot study aimed to assess the feasibility of enriching and detecting CTCs from both peripheral and ovarian vein blood samples in rare EOC subtypes.
Materials And Methods: Blood samples were collected from the peripheral and ovarian veins of 20 patients with rare EOC.
Unravelling the biological and clinical challenges of circulating tumour cells in epithelial ovarian carcinoma.
Cancer Lett
November 2024
Department of Histopathology, School of Medicine, Trinity College Dublin, Dublin, Ireland; Department of Obstetrics and Gynaecology, School of Medicine, Trinity College Dublin, Dublin, Ireland; Trinity St. James's Cancer Institute, Trinity College Dublin, Dublin, Ireland. Electronic address: shotool
Article Synopsis
- Epithelial ovarian carcinoma (EOC) is a significant health threat for women, being the most deadly gynecological cancer primarily due to late diagnoses and high recurrence rates.
- Circulating tumor cells (CTCs) are a rare type of cancer cell that spread into the bloodstream and may serve as useful biomarkers for monitoring EOC, as they can be obtained through minimally invasive liquid biopsies.
- Despite their potential, the unique characteristics of EOC complicate the detection and analysis of CTCs, posing challenges for their use in clinical settings.
Article Synopsis
- - The study investigates the use of Doppel, a prion-like protein absent in healthy female tissues, as a specific biomarker for detecting ovarian cancer (OC) early, distinguishing different subtypes and stages with high sensitivity and specificity.
- - Increased levels of Doppel in the sera of OC patients were found across three cohorts, allowing researchers to categorize the tumors into Doppel-high and Doppel-low groups, which are linked to differences in cancer characteristics.
- - The research also reveals that Doppel induces a process called epithelial-mesenchymal transition (EMT) and creates an immunosuppressive environment, suggesting a correlation between Doppel levels and circulating tumor cell (CTC) dissemination in the bloodstream.
Plasminogen activator inhibitor 1 is associated with high-grade serous ovarian cancer metastasis and is reduced in patients who have received neoadjuvant chemotherapy.
Front Cell Dev Biol
December 2023
Department of Histopathology and Morbid Anatomy, School of Medicine, Trinity College Dublin, Dublin, Ireland.
High-grade serous ovarian cancer (HGSOC) is the most prevalent and deadliest subtype of epithelial ovarian cancer (EOC), killing over 140,000 people annually. Morbidity and mortality are compounded by a lack of screening methods, and recurrence is common. Plasminogen-activator-inhibitor 1 (PAI-1, the protein product of SERPIN E1) is involved in hemostasis, extracellular matrix (ECM) remodeling, and tumor cell migration and invasion.
View Article and Find Full Text PDFPurification of Circulating Tumor Cells Based on Multiantibody-Modified Magnetic Nanoparticles and Molecular Analysis toward Epithelial Ovarian Cancer Detection.
ACS Sens
October 2023
Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
Circulating tumor cells (CTCs) are valuable circulating biomarkers of cancer, which carry primary tumor information and may provide real-time assessment of tumor status as well as treatment response in cancer patients. Herein, we developed a novel assay for accurate diagnosis and dynamic monitoring of epithelial ovarian cancer (EOC) using CTC RNA analysis. Multiantibody-modified magnetic nanoparticles were prepared for purification of EOC CTCs from whole blood samples of clinical patients.
View Article and Find Full Text PDF